Clinical trial for development of topical rapamycin treatment for rosacea
- Conditions
- rosacea
- Registration Number
- JPRN-UMIN000008315
- Lead Sponsor
- Department of Dermatology Graduate School of Medicine, Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Not provided
1) Patients who cannot comply with the treatment plan. 2) Patients who are allergic to macrolide antibiotics. 3) Patients who received oral administration of rapamycin or RAD001 within six months prior to the study entry. 4) Patients who received oral administration of macrolide antibiotics for more than 7 days within three months prior to the study entry. 5) Patients who received topical steroid treatment within three months prior to the study entry. 6) Patients who received topical treatment of tacrolimus, nadifloxacin, clindamycin or adapalene within a month prior to the study entry. 7) Patients who have a large wound or scar on the face, which would interfere the treatment or the assessment. 8) Patients who are pregnant or lactating. 9) Patients under 18 years of age. 10) Patients who were judged unsuitable for this study by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in redness and size of eruptions after 4 and 8 weeks of treatment, and at 4 and 8 weeks after end of treatment
- Secondary Outcome Measures
Name Time Method Appearance of contact dermatitis Rapamycin levels in whole blood histological findings in specimens of skin tissue in the cases who agree with skin biopsy